Update on adjuvant therapy of colon cancer

Tumori

Volumn 83, Issue 1 SUPPL., 1997, Pages

  Macdonald, John S ^a   Haller, Daniel ^b  

^a TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADJUVANT THERAPY; COLON CANCER; CONFERENCE PAPER; HUMAN;

EID: 0030988176     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/03008916970831s119     Document Type: Conference Paper

References (17)

1. American Cancer Society: Cancer facts and figures-1995, p. 6, 1995.
2. Anonymous. The efficacy and the group C status of levamisole and 5-fluorouracil for patients with Dukes' C colon cancer. National Cancer Institute Update, October, 1989.
3. Buyse M., Zeleniuch-Jacquotte A., Chalmers T.C.: Adjuvant therapy of colon cancer: why we still don't know. JAMA, 259: 3571-3578, 1988.
4. Crowley J.J.: Perioperative portal vein chemotherapy. ASCO Educational Book, p. 171, 1994.
5. de Haas-Kock D., Baeten C., Jager J., Langendijk Schouten L., Arends J.: The prognostic significance of the lateral resection margin in rectal cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Koln, Germany, January 1995.
6. Francini G., Petrioli R., Lorenzini L., Mancini S., Armenio S., Tanzini G., Marsil S., Aquino A., Marzocca G., Civitellis C., Mariani L., De Sando D., Bovenga S., Lorenzi M.: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology, 106: 899-906, 1994.
7. Haller D.G., Catalano P.J., Macdonald J.S., Mayer R.J.: Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc. Am. Soc. Clin. Oncol., 15: 486; 1996.
8. Hodi F.S., Catalano P., Macdonald J.S., Mayer R.J., Haller D.G.: Age as a factor influencing the toxicity of adjuvant chemotherapy for colorectal cancer. Pending submission, 8/96.
9. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT): Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939-944, 1995.
10. Moertel C.G., Fleming T.R., Macdonald J.S.: Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J. Clin. One., 11: 2386-2390, 1993.
11. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangan C.M., Ungerleider J.S., Eerson W.A., Tormey D.C., Glick J.H., Veeder M.H., Maillaird J.A.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Int. Med., 122: 321-326, 1995.
12. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., Veeder M.H., Mailliard J.A.: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352-358, 1990.
13. O'Connell J.M., Laurie J.A., Shepherd L., Kahn M.J., Pazdur R., Fitzgibbons R.J., Erlichman C., Wieand H.S.: A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the North Central Cancer Treatment Group and The National Cancer Institute of Canada Clinical Trials Group. Proc. Am. Soc. Clin. Oncol., 15: 478, 1996.
14. O'Connell M., Mailliard J., Macdonald J.S.: An intergroup trial of intensive course 5-FU and low dose leucovonn as surgical adjuvant therapy for high risk colon cancer. Proc. Am. Soc. Clin. Oncol., 12: 190, 1993.
15. Piedbois P., Buyse M., Gray R., Clarke M., Wolkmark N., Metzger V., Fielding L.P., Gray P., Taylor I., Wereldsma J., Ryan J., Marsoni S., Gruenagel H.H.: Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc. Am. Soc. Clin. Oncol., 14: 192, 1995.
16. Riethmuller G., Schneider-Gadicke E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Pichlmaier H., Hirche H., Pichlmayr R., Buggisch P., Witte J.: Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-183, 1994.
17. Wolmark N., Rockette H., Mamounas E.P., Jones J., Petrelli N., Atkins J., Dimitrov N., Pugh R., Wickerham D.L., Wieand S., Fisher B.: The relative efficacy of 5-FU + leucovorin (FU-LV), 5-FU + levamisole (FU-LEV), and 5-FU + leucovorin + levamisole (FU-LV-LEV) in patients with Dukes' B and C carcinoma of the colon: First Report of NSABP CO-4. Proc. Am. Soc. Clin. Oncol., 15: 460, 1996.